RT Journal Article
SR Electronic
T1 Genomic and immune determinants of resistance to anti-CD38 monoclonal antibody-based therapy in relapsed refractory multiple myeloma
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.12.04.23299287
DO 10.1101/2023.12.04.23299287
A1 Ziccheddu, Bachisio
A1 Giannotta, Claudia
A1 D’Agostino, Mattia
A1 Bertuglia, Giuseppe
A1 Saraci, Elona
A1 Oliva, Stefania
A1 Genuardi, Elisa
A1 Papadimitriou, Marios
A1 Diamond, Benjamin
A1 Corradini, Paolo
A1 Coffey, David
A1 Landgren, Ola
A1 Bolli, Niccolò
A1 Bruno, Benedetto
A1 Boccadoro, Mario
A1 Massaia, Massimo
A1 Maura, Francesco
A1 Larocca, Alessandra
YR 2023
UL http://medrxiv.org/content/early/2023/12/04/2023.12.04.23299287.abstract
AB Anti-CD38 antibody therapies have transformed multiple myeloma (MM) treatment. However, a large fraction of patients inevitably relapses. To understand this, we investigated 32 relapsed MM patients treated with daratumumab, lenalidomide, and dexamethasone (Dara-Rd; NCT03848676). Whole genome sequencing (WGS) before and after treatment pinpointed genomic drivers associated with early progression, including RPL5 loss and APOBEC mutagenesis. Flow cytometry on 202 blood samples, collected every three months until progression for 31 patients, revealed distinct immune changes significantly impacting clinical outcomes. Progressing patients exhibited significant depletion of CD38+ NK cells, persistence of T cell exhaustion, and reduced depletion of T-reg cells over time. These findings underscore the influence of immune composition and daratumumab-induced immune changes in promoting MM resistance. Integrating genomics and flow cytometry unveiled associations between adverse genomic features and immune patterns. Overall, this study sheds light on the intricate interplay between genomic complexity and the immune microenvironment driving resistance to Dara-Rd.Competing Interest StatementOL has received research funding from: National Institutes of Health (NIH), National Cancer Institute (NCI), U.S. Food and Drug Administration (FDA), Multiple Myeloma Research Foundation (MMRF), International Myeloma Foundation (IMF), Leukemia and Lymphoma Society (LLS), Myeloma Solutions Fund (MSF), Paula and Rodger Riney Multiple Myeloma Research Program Fund, the Tow Foundation, Perelman Family Foundation, Rising Tide Foundation, Amgen, Celgene, Janssen, Takeda, Glenmark, Seattle Genetics, Karyopharm; Honoraria/ad boards: Adaptive, Amgen, Binding Site, BMS, Celgene, Cellectis, Glenmark, Janssen, Juno, Pfizer; and serves on Independent Data Monitoring Committees (IDMCs) for clinical trials lead by Takeda, Merck, Janssen, Theradex. NB has received honoraria from Janssen, Pfizer, GSK, Jazz, Takeda. Clinical TrialNCT03848676Funding StatementThis study was funded and supported by Associazione Italiana per la Ricerca sul Cancro (AIRC IG 20541). This work was supported by the Myeloma Solutions Fund (MSF), Paula and Rodger Riney Multiple Myeloma Research Program Fund, the Tow Foundation, Sylvester Comprehensive Cancer Center NCI Core Grant (P30 CA 240139). FM is supported by the American Society of Hematology (ASH), Leukemia & Lymphoma Society (LLS), and by International Myeloma Society (IMS). N.B. Is supported by the Associazione Italiana per la Ricerca sul Cancro (AIRC Investigator Grant n. 25739) and by the European Research Council under the European Union Horizon 2020 research and innovation program (grant agreement No. 817997) Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:32 relapsed/refractory MM patients were enrolled after informed consent and treated with Dara-Rd therapy (NCT03848676). The protocol was approved by the Comitato Etico Interaziendale Azienda Ospedaliera Universitaria, Citta' della Salute e della Scienza di Torino, Azienda Ospedaliera Ordine Mauriziano di Torino, Azienda Ospedaliera Locale citta' di TorinoI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThese data (whole genome sequencing) will be submitted to EGA. The Kydar scRNA-seq data are publicly available at the National Center for Biotechnology Information Gene Expression Omnibus (accession no. GSE161195). The CoMMpass data was downloaded from the MMRF researcher gateway portal (https://research.themmrf.org). CoMMpass raw data are accessible on dbgap: phs000748.v1.p1.